TRAVERSE BIOSCIENCES, INC. — Department of Health and Human Services STTR Phase I: DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage dr
TRAVERSE BIOSCIENCES, INC. — STTR Phase I award from Department of Health and Human Services.
- Amount
- $223,797
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Solicitation
- PA13-235
- NAICS
- —
- Place of performance
- NY
- Period
- —
Description
DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprietary chemically modified curcumin developed by the co-inventor of Periostat(R) and Oracea(R), currently the only FDA-approved MMP inhibitors. Osteoarthritis [OA] is the most common form of joint disease and a leading cause of disability in the elderly. OA currently affects 27M Americans, and it is characterized by progressive destruction of the articular cartilage and loss of its extracellular matrix. Current treatments for OA involve pain relief and anti-inflammatory compounds to increase tolerance for daily activities. However, available therapies are primarily palliative, have low efficacy and fail to prevent pro